MyFinsight
Home
Blog
About
Contact
Back
Cash Flow
Transcode Therapeutics, Inc. (RNAZ)
Transcode Therapeutics, Inc. (RNAZ)
source: myfinsight.com
Download
Download image
Net change in cash
-$4,978,067
Non-cash acquired
in-process research and...
$10,426,257
Accounts payable and
accrued expenses
$1,774,088
Grants receivable
-$952,460
Deferred tax liability
$231,309
Change in fair value of
warrant liabilities
$125,348
Deferred grant income
$85,262
Depreciation
$23,936
Net cash used in
operating activities
-$4,978,067
Canceled cashflow
$13,618,660
Net loss
-$17,785,071
Prepaid expenses and
other current assets
$695,656
Change in fair value of
contingent consideration
-$116,000
Back